Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High‐dose eicosapentaenoic ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatt, Deepak L., Steg, Ph. Gabriel, Brinton, Eliot A., Jacobson, Terry A., Miller, Michael, Tardif, Jean‐Claude, Ketchum, Steven B., Doyle, Ralph T., Murphy, Sabina A., Soni, Paresh N., Braeckman, Rene A., Juliano, Rebecca A., Ballantyne, Christie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2017
Materias:
Trial Designs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396348/
https://www.ncbi.nlm.nih.gov/pubmed/28294373
http://dx.doi.org/10.1002/clc.22692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396348/
https://www.ncbi.nlm.nih.gov/pubmed/28294373
http://dx.doi.org/10.1002/clc.22692

Ejemplares similares